Education
About Us
Working with TipRanks
Follow Us
Auna S.A. Class A (AUNA)
NYSE:AUNA
Top Page
Auna S.A. Class A
(NYSE:AUNA)
Rating:65Neutral
Price Target:
$7.00
▲(11.29% Upside)
Auna S.A. Class A (AUNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$465.54M
Dividend YieldN/A
Average Volume (3M)24.26K
Price to Earnings (P/E)11.0
Beta (1Y)0.97
Revenue Growth6.97%
EPS GrowthN/A
CountryUS
Employees14,605
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.33
Shares Outstanding30,095,388
10 Day Avg. Volume34,262
30 Day Avg. Volume24,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.24
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda1.37
Forecast
1Y Price Target
$7.00Price Target Upside11.29% Upside
Rating ConsensusHold
Number of Analyst Covering0
Auna S.A. Class A Business Overview & Revenue Model
Company DescriptionAuna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.
How the Company Makes MoneyAuna S.A. makes money through a diversified revenue model centered around its healthcare services and related offerings. The company's key revenue streams include fees for medical services provided at its hospitals and clinics, which encompasses inpatient and outpatient care, surgical procedures, and diagnostic services. Additionally, Auna generates income through insurance plans and prepaid healthcare packages, offering clients a range of coverage options. The company also benefits from strategic partnerships with local and international medical institutions and insurance companies, enhancing its service offerings and expanding its customer base. Furthermore, Auna's investment in healthcare technology and innovation helps optimize operational efficiency and patient satisfaction, contributing positively to its financial performance.
Auna S.A. Class A Earnings Call Summary
Earnings Call Date:Aug 19, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 25, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view with notable growth in consolidated FX-neutral EBITDA and strong performance in Peru and Mexico. However, challenges such as decreased capacity utilization, flat revenue in Colombia, and market softness in Mexico were acknowledged.Q2-2025 Updates
Positive Updates
Consolidated FX-neutral EBITDA Growth
In the second quarter, Auna achieved a 5% growth in consolidated FX-neutral EBITDA, with contributions from Mexico, Colombia, and Peru.
Peru's Performance in Healthcare and Oncology
Peru's healthcare services saw a 5% revenue growth driven by increased surgery volumes and price increases. OncoSalud, the health plan side, delivered solid revenue and EBITDA growth, achieving a record low oncology MLR.
Mexico's Revenue Growth
Mexico's revenue grew 5% year-over-year, driven by higher average tickets for surgeries and emergency treatments, despite market softness.
Colombia's Improved EBITDA and Margin
Colombia's EBITDA increased by 9%, and margin expanded by 1.4 percentage points year-over-year, with a more profitable mix of payers and improved payment flows.
Stable Financial Position
Auna maintained a healthy debt structure and improved its maturity profile by refinancing over $62 million of short-term debt.
Negative Updates
Capacity Utilization Decline
Auna's total capacity utilization decreased by 2.5 percentage points to 64%, primarily due to intentional growth slowing in Colombia.
Market Softness in Mexico
Mexico's market conditions remained soft due to tariff uncertainty, impacting formal employment and leading to a decline in surgery volumes and emergency visits.
Revenue Flat in Colombia
Colombia's revenue remained flat year-over-year as Auna focused on risk mitigation and improving cash conversion cycles.
Company Guidance
During Auna's Second Quarter 2025 Earnings Conference Call, the company reported key financial metrics and guidance, indicating a 5% growth in consolidated FX-neutral EBITDA. This growth was driven by improvements across their operations in Mexico, Colombia, and Peru. In Peru, revenue increased by 5%, largely due to higher surgery volumes and price adjustments, while OncoSalud saw a 10% growth in general healthcare plans. Mexico's revenue rose by 5% year-over-year, despite a decline in surgery volumes, attributed to higher average service tickets and repricing strategies. Colombia's EBITDA increased by 9% with a margin expansion of 1.4 percentage points, supported by effective risk-sharing models and improved cash flows. The company maintained a healthy debt structure with a commitment to reducing leverage to 3x net debt to EBITDA, and despite a 13% decrease in cash position, they reported a 6x increase in adjusted net income, reflecting effective financial management and positive FX variances.Auna S.A. Class A Financial Statement Overview
Summary
Auna S.A. Class A shows strong profitability margins but faces challenges with declining revenue growth. The balance sheet indicates high leverage, posing financial risks despite decent ROE. The cash flow is a positive aspect, with growth and strong cash generation relative to net income. Overall, financial performance is mixed, with a need to improve revenue growth and manage leverage.Income Statement
Auna S.A. Class A has shown a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 38.89% and a net profit margin of 3.65%, which are relatively healthy. However, the revenue growth rate is negative at -0.61%, indicating a decline in revenue. The EBIT and EBITDA margins are strong at 19.11% and 23.91%, respectively, suggesting efficient operations. Overall, while profitability metrics are solid, the negative revenue growth is a concern.65
Positive
Balance Sheet
The balance sheet of Auna S.A. Class A reveals a high debt-to-equity ratio of 2.46, indicating significant leverage, which could pose financial risks. The return on equity (ROE) is moderate at 10.61%, reflecting decent profitability relative to shareholder equity. The equity ratio stands at 22.93%, suggesting a moderate level of equity financing. While the company maintains profitability, the high leverage is a potential risk factor.55
Neutral
Cash Flow
Auna S.A. Class A's cash flow statement shows positive trends. The free cash flow growth rate is 5.27%, indicating an improvement in cash generation. The operating cash flow to net income ratio is 0.30, and the free cash flow to net income ratio is 0.76, suggesting that the company is generating sufficient cash relative to its net income. Overall, the cash flow position is strong, with positive growth and adequate coverage ratios.70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.33B | 4.39B | 3.88B | 2.45B | 1.92B | 1.44B |
| Gross Profit | 1.70B | 1.73B | 1.44B | 879.70M | 686.93M | 529.43M |
| EBITDA | 1.10B | 975.27M | 647.30M | 299.14M | 170.15M | 108.36M |
| Net Income | 237.26M | 110.27M | -253.92M | -85.61M | -26.47M | -7.10M |
Balance Sheet | ||||||
| Total Assets | 7.17B | 7.08B | 7.69B | 6.59B | 2.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 287.11M | 335.97M | 334.26M | 208.69M | 138.77M | 343.45M |
| Total Debt | 3.70B | 3.77B | 3.92B | 3.51B | 1.49B | 1.35B |
| Total Liabilities | 5.37B | 5.46B | 5.91B | 5.04B | 2.28B | 2.00B |
| Stockholders Equity | 1.64B | 1.48B | 1.47B | 1.06B | 495.82M | 600.93M |
Cash Flow | ||||||
| Free Cash Flow | 497.19M | 577.64M | 417.25M | 10.67M | -106.03M | 27.38M |
| Operating Cash Flow | 648.33M | 668.50M | 582.41M | 162.64M | 183.34M | 156.30M |
| Investing Cash Flow | -229.58M | -236.82M | -173.15M | -3.21B | -291.99M | -125.93M |
| Financing Cash Flow | -394.72M | -418.12M | -370.00M | 3.13B | -102.13M | 272.70M |
Auna S.A. Class A Technical Analysis
Positive
6.29
Price Trends
6.29
Positive
6.52
Negative
6.99
Negative
Market Momentum
-0.01
Negative
51.19
Neutral
40.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUNA, the sentiment is Positive. The current price of 6.29 is above the 20-day moving average (MA) of 6.26, above the 50-day MA of 6.29, and below the 200-day MA of 6.99, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 40.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUNA.
Auna S.A. Class A Peers Comparison
Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $465.54M | 10.98 | 9.93% | ― | 6.97% | ― | |
62 Neutral | $170.07M | 3.81 | -7.92% | ― | 6.32% | 344.42% | |
55 Neutral | $6.43B | -2.52 | -4.30% | 5.96% | 15.30% | 11.62% | |
54 Neutral | $152.58M | 12.68 | -5.98% | ― | -41.31% | -163.08% | |
47 Neutral | $413.65M | ― | -71.30% | ― | ― | 21.30% | |
46 Neutral | $59.87M | ― | -138.17% | ― | 4.20% | -54.16% | |
39 Underperform | $22.68M | ― | 14.03% | ― | -29.82% | -2.57% |
* General Sector Average
Performance Comparison
AUNA
Auna S.A. Class A
6.29
-0.55
-8.04%
CCM
Concord Medical Services
5.22
-1.08
-17.14%
CMPS
COMPASS Pathways
4.42
-2.80
-38.78%
DCGO
DocGo
1.56
-1.99
-56.06%
PIII
P3 Health Partners
8.33
-14.66
-63.77%
BTMD
biote
3.44
-2.55
-42.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.